No Data
No Data
Mesoblast Starts Recruitment for Phase Three Low Back Pain Trial
Mesoblast (ASX:MSB) opened recruitment for its phase three trial investigating the use of its cell therapy product rexlemestrocel-L in patients with chronic low back pain, according to a Monday
Up 308% in 6 Months, Why Is the Mesoblast Share Price Tumbling Today?
Shares in the S&P/ASX 300 Index (ASX: XKO) biotech company closed on Friday trading for $1.15. In morning trade on Monday, they are changing hands for $1.135 apiece, down 1.3%.
AU Evening Wrap: ASX 200 Falls on Metal Stocks; Droneshield Rebounds
Australia stocks were lower after the close on Friday, as losses in the Gold, Metals & Mining and Materials sectors led shares lower.
Mesoblast Refiles Biological License Application With the Us FDA for Cell Therapy; Shares Fall 6%
Mesoblast (ASX:MSB) refiled the biological license application with the US Food and Drug Administration for the use of its Ryoncil-branded remestemcel-L cell therapy in pediatric patients with steroid
What's Going on With the Mesoblast Share Price Today?
The Mesoblast Ltd (ASX: MSB) share price is having a disappointing session on Tuesday.
Mesoblast Resubmits Biologics License Application (BLA) With United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil (remestemcel-L) in the treatment of children with SR-aGVHD.
No Data